Osstell announces appointment of new CEO
Aug 19, 2022
Osstell today announced that Malin Gustavsson has been appointed Chief Executive Officer (CEO) and will assume the position end of September.
Osstell, today announced that Malin Gustavsson has been appointed Chief Executive Officer (CEO) and will assume the position end of September.
Malin Gustavsson will succeed Jonas Ehinger, who will take on a new challenge. Gustavsson has more than 15 years of senior management experience in the medical device industry, including Straumann and the past 9 years at Elos Medtech, a leading global development and manufacturing company for medical devices, as Global Communication & Marketing Director.
“I am very happy to have been entrusted to lead and contribute to the company’s continued growth together with the board and the team at Osstell. Since I worked in the dental industry for many years, I know the company from before and its strong brand. I am very much looking forward to taking over as CEO at Osstell shortly and to getting to know both the customers, partners and the employees more closely, along with its business, to drive the company’s strategy with a strong focus on delivering clinical value to the market.”, said Malin Gustavsson.
Jonas Ehinger and Malin Gustavsson
Klaus Maier, W&H Group CEO, commented “Malin’s extensive experience within the dental market, her business development and managerial skills will help drive further growth of Osstell and will be of great value to the W&H Group. We are excited to welcome Malin”. Mr Maier added “We are sad to see Jonas leave Osstell and the W&H Group but are very grateful for his contributions and dedicated continuous development and now wish him the very best in his new assignment.”
Ehinger will take on a new CEO assignment outside the dental and medical industry. Jonas Ehinger has led Osstell through a strong growth phase and different owner structures during the past twelve years, developing and executing the strategy focusing on Osstell’s proprietary ISQ technology, and now OsstellConnect as a strategy for the coming years. Osstell’s clinical relevance and value for clinicians and patients will remain the focus of the company moving forward.